Literature DB >> 28655582

Prevalence of Clostridium perfringens toxin in patients suspected of having antibiotic-associated diarrhea.

Young Jin Kim1, Si Hyun Kim2, Junggu Ahn3, Soongmoon Cho4, Dongchun Kim4, Kwanghyun Kim4, Heegun Lee4, Hyunwoo Son4, Hee Joo Lee1, Dongeun Yong5, Jun Yong Choi6, Hye Ran Kim7, Jeong Hwan Shin8.   

Abstract

BACKGROUND: Although Clostridium perfringens has been reported as a cause of antibiotic-associated diarrhea (AAD), it is uncommon to detect this pathogen in clinical microbiology laboratories in Korea. The aim of this study was to investigate the prevalence of C. perfringens toxin in patients suspected of having AAD.
METHODS: A total of 135 stool specimens submitted to a clinical microbiology laboratory for C. difficile toxin assay were tested. We tried to detect both C. difficile and C. perfringens toxins using the Seeplex Diarrhea ACE Detection kit (Seegene, Seoul, Korea). We evaluated the prevalence of 10 bacteria and 5 viruses.
RESULTS: A total of 40 Clostridium spp. were detected in 34 specimens (29.6%). The C. perfringens toxin was detected in 14 of 135 specimens (10.4%), while C. difficile toxin was detected in 26 specimens (19.3%). Other bacteria and viruses, including 8 Aeromonas spp., were detected in 15 specimens. All tests were negative in 92 of the 135 specimens (68.1%).
CONCLUSION: Clostridium perfringens toxin is relatively common, and we should consider the possibility of its presence in patients suspected of having AAD, especially if C. difficile tests are negative.
Copyright © 2017 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Antibiotic-associated diarrhea; Clostridium perfringens

Mesh:

Substances:

Year:  2017        PMID: 28655582     DOI: 10.1016/j.anaerobe.2017.06.015

Source DB:  PubMed          Journal:  Anaerobe        ISSN: 1075-9964            Impact factor:   3.331


  7 in total

1.  Prevalence and characterization of Clostridium perfringens toxinotypes among patients with antibiotic-associated diarrhea in Iran.

Authors:  Masoumeh Azimirad; Fatemeh Gholami; Abbas Yadegar; Daniel R Knight; Sharareh Shamloei; Hamid Asadzadeh Aghdaei; Mohammad Reza Zali
Journal:  Sci Rep       Date:  2019-05-24       Impact factor: 4.379

Review 2.  Unraveling the Role of Vegetables in Spreading Antimicrobial-Resistant Bacteria: A Need for Quantitative Risk Assessment.

Authors:  Christina Susanne Hölzel; Julia Louisa Tetens; Karin Schwaiger
Journal:  Foodborne Pathog Dis       Date:  2018-11       Impact factor: 3.171

3.  Phylogenomic analysis of gastroenteritis-associated Clostridium perfringens in England and Wales over a 7-year period indicates distribution of clonal toxigenic strains in multiple outbreaks and extensive involvement of enterotoxin-encoding (CPE) plasmids.

Authors:  Raymond Kiu; Shabhonam Caim; Anais Painset; Derek Pickard; Craig Swift; Gordon Dougan; Alison E Mather; Corinne Amar; Lindsay J Hall
Journal:  Microb Genom       Date:  2019-09-20

4.  Protecting intestinal epithelial cells against deoxynivalenol and E. coli damage by recombinant porcine IL-22.

Authors:  Yunyun Li; Jinquan Wang; Yuchen Li; Haiqin Wu; Shiyi Zhao; Qinghua Yu
Journal:  Vet Microbiol       Date:  2019-03-13       Impact factor: 3.293

5.  Prevalence and Genetic Diversity of Clostridium perfringens Isolates in Hospitalized Diarrheal Patients from Central China.

Authors:  Baoya Wang; Wenjuan Dong; Liyan Ma; Yonghui Dong; Shanmei Wang; Youhua Yuan; Qiong Ma; Junhong Xu; Wenjuan Yan; Jing Nan; Qi Zhang; Wenbo Xu; Bing Ma; Yafei Chu; Jiangfeng Zhang; Li Li; Yi Li
Journal:  Infect Drug Resist       Date:  2021-11-15       Impact factor: 4.003

Review 6.  An update on the human and animal enteric pathogen Clostridium perfringens.

Authors:  Raymond Kiu; Lindsay J Hall
Journal:  Emerg Microbes Infect       Date:  2018-08-06       Impact factor: 7.163

7.  A worldwide systematic review and meta-analysis of bacteria related to antibiotic-associated diarrhea in hospitalized patients.

Authors:  Hamid Motamedi; Matin Fathollahi; Ramin Abiri; Sepide Kadivarian; Mosayeb Rostamian; Amirhooshang Alvandi
Journal:  PLoS One       Date:  2021-12-08       Impact factor: 3.240

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.